CovidChloroV1, Main, Corpus, bibRecord, 000A82

Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.

Identifieur interne : 000A82 ( Main/Corpus ); précédent : 000A81; suivant : 000A83

Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.

Auteurs : Ernesto Carafoli

Source :

Biochemical and biophysical research communications [ 1090-2104 ] ; 2021.

RBID : pubmed:33028485

English descriptors

KwdEn :
- COVID-19 (drug therapy), COVID-19 (prevention & control), Chloroquine (chemistry), Chloroquine (pharmacology), Chloroquine (therapeutic use), Humans (MeSH), Hydroxychloroquine (chemistry), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Primary Prevention (MeSH).
MESH :
- chemical , chemistry : Chloroquine, Hydroxychloroquine.
- drug therapy : COVID-19.
- chemical , pharmacology : Chloroquine, Hydroxychloroquine.
- prevention & control : COVID-19.
- chemical , therapeutic use : Chloroquine, Hydroxychloroquine.
- Humans, Primary Prevention.

Abstract

At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: "This is a long story, that shouldn't be long, but it will take a long time to make it short". As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it.

DOI: 10.1016/j.bbrc.2020.09.128
PubMed: 33028485
PubMed Central: PMC7524676

Links to Exploration step

pubmed:33028485

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.</title>
<author><name sortKey="Carafoli, Ernesto" sort="Carafoli, Ernesto" uniqKey="Carafoli E" first="Ernesto" last="Carafoli">Ernesto Carafoli</name>
<affiliation><nlm:affiliation>Venetian Institute of Molecular Medicine, University of Padova, Italy. Electronic address: ernestocarafoli@gmail.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33028485</idno>
<idno type="pmid">33028485</idno>
<idno type="doi">10.1016/j.bbrc.2020.09.128</idno>
<idno type="pmc">PMC7524676</idno>
<idno type="wicri:Area/Main/Corpus">000A82</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A82</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.</title>
<author><name sortKey="Carafoli, Ernesto" sort="Carafoli, Ernesto" uniqKey="Carafoli E" first="Ernesto" last="Carafoli">Ernesto Carafoli</name>
<affiliation><nlm:affiliation>Venetian Institute of Molecular Medicine, University of Padova, Italy. Electronic address: ernestocarafoli@gmail.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Biochemical and biophysical research communications</title>
<idno type="eISSN">1090-2104</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (drug therapy)</term>
<term>COVID-19 (prevention & control)</term>
<term>Chloroquine (chemistry)</term>
<term>Chloroquine (pharmacology)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (chemistry)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Primary Prevention (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Primary Prevention</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: "This is a long story, that shouldn't be long, but it will take a long time to make it short". As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33028485</PMID>
<DateCompleted><Year>2021</Year>
<Month>03</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>538</Volume>
<PubDate><Year>2021</Year>
<Month>01</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.</ArticleTitle>
<Pagination><MedlinePgn>156-162</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0006-291X(20)31881-7</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2020.09.128</ELocationID>
<Abstract><AbstractText>At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: "This is a long story, that shouldn't be long, but it will take a long time to make it short". As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it.</AbstractText>
<CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carafoli</LastName>
<ForeName>Ernesto</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Venetian Institute of Molecular Medicine, University of Padova, Italy. Electronic address: ernestocarafoli@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of competing interest I declare no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>09</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>3</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>26</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33028485</ArticleId>
<ArticleId IdType="pii">S0006-291X(20)31881-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbrc.2020.09.128</ArticleId>
<ArticleId IdType="pmc">PMC7524676</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Eur J Intern Med. 2020 Dec;82:38-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32859477</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS. 2001 Nov 23;15(17):2221-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11698694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rev Allergy Immunol. 2012 Apr;42(2):145-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21221847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Oct;108(4):766-769</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32344449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Malar J. 2011 May 09;10:116</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21554692</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 1988 Jul;2(10):2557-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3290025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Parasitol. 1992 May;74(3):362-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1582489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Oct;56(4):106144</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32853673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 2018 Oct;41(10):919-931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2001 Feb;20(3):131-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11166661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Aug;97:396-403</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32623082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105960</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1978 Jul;75(7):3327-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2001 Feb;20(3):137-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11166662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intervirology. 1998;41(6):261-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10325536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Ther. 1993 Feb-Mar;57(2-3):203-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8361993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Feb;23(2):300-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23208422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 1993 Sep;80(1):127-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8244453</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32363212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2001 Jan 25;344(4):257-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11172152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Microbiol. 1997;51:97-123</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9343345</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Jun 16;172(12):819-821</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2018 Dec;14(12):693-703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30401979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1984 Dec;52(3):857-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6492263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 1997 Jan;24(1):55-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9002011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1998 Oct 10;352(9135):1224-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9777866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1998 Jun 20;351(9119):1825</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9652658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Sep;585(7826):588-590</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32698190</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Jun 13;395(10240):1820</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32511943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11865-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8876229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2019 Sep 27;294(39):14406-14421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31399512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Oct;63(10):1515-1521</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32418114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Death Dis. 2020 Jul 8;11(7):516</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32641762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Feb;75(3):1236-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11152497</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A82 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A82 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33028485
   |texte=   Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33028485" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.

Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki